Ethiopia Antimicrobial Resistance Surveillance Plan
Η ανακάλυψη πριν από 80 περίπου χρόνια ότι ουσίες που παράγονται από μύκητες ή βακτήρια μπορούν να χρησιμοποιηθούν θεραπευτικά για την ίαση διαφόρων λοιμώξεων, έφε...ε επανάσταση στα τότε ιατρικά δεδομένα. Οι λοιμώδεις νόσοι αποτελούσαν τότε την πρώτη αιτία θανάτου για κάθε ηλικιακή ομάδα. Το γεγονός αυτό ανατράπηκε με την έναρξη της χρήσης των ουσιών αυτών, που ονομάστηκαν αντιβιοτικά λόγω της ιδιότητας τους να καταστρέφουν τα μικρόβια. Έκτοτε εκατομμύρια ζωές έχουν σωθεί με τη χορήγηση αντιβιοτικών για την αντιμετώπιση σοβαρών λοιμώξεων. Σήμερα, οκτώ δεκαετίες μετά, οι πολύτιμες αυτές για τον άνθρωπο ουσίες χάνουν με συνεχώς επιταχυνόμενο ρυθμό την αποτελεσματικότητά τους λόγω επίτασης του φαινομένου της Μικροβιακής Αντοχής στα αντιβιοτικά.
more
Когда возникают ситуации, при которых нежелательные явления справедливо или ошибочно связывают с вакцинацией, они могут подорвать доверие к вакцинам и официальны...м органам, осуществляющим их введение. Этот документ предоставляет научные данные, помимо рекомендаций ВОЗ, относительно создания и восстановления доверия к вакцинам и вакцинации как в процессе осуществления работы, так и в период кризисных ситуаций. Данные привлекают внимание к широкому набору научных лабораторных фактов и фактам, полученным при полевых работах в области психологии и коммуникаций. Он рассматривает, как люди принимают решения по поводу вакцинации; почему некоторые лица не доверяют вакцинации; и факторы, которые вызывают критические ситуации, уделяя внимание тому, как создавать доверие, слушать и понимать людей, создавать взаимоотношения, сообщать о рисках и формировать сообщения для аудитории, что может смягчать кризисные ситуации. Этот документ предоставляет базисные знания заинтересованным сторонам, которые разрабатывают коммуникационные стратегии или содействуют проведению семинаров по коммуникациям и деятельности по созданию доверия в связи с вакцинами и иммунизацией, таким как подразделения программы иммунизации, министры здравоохранения, подразделения по связи с общественностью и укреплению здоровья, преподаватели по коммуникации относительно безопасности вакцин и консультативные органы по иммунизации
more
This document aims to describe a minimum set of surveillance activities recommended at the national level to detect and monitor the relative prevalence of SARS-CoV-2 variants and outline a set of activities for the characterization and assessment of risk posed by these variants. A set of indicators ...is also provided to standardize monitoring and public reporting of variant circulation.
The document is primarily intended for national and sub-national public health authorities and partners who support implementation of surveillance for SARS-CoV-2 variants
more
SARS-CoV-2 infections among children and adolescents cause less severe illness and fewer deaths compared to adults. While a less severe course of infection is a positive outcome, there are concerns that mild symptoms may have led to less testing, resulting in fewer identified cases of COVID-19 in ch...ildren. If children with mild or no symptoms transmit the disease, they may act as drivers of transmission within their communities. Understanding symptoms, infectivity and patterns of SARS-CoV-2 transmission in children and adolescents is essential for developing, adapting and improving control measures for COVID-19 across all ages. This is a summary of the current knowledge around SARS-CoV-2 infection acquisition and transmission and COVID-19 disease symptoms in children and adolescents. It aims to inform decisions, based on local contexts, on how to best keep schools, kindergarten and day-care facilities open and what advice to apply to intergenerational mixing.
more
Les infections au SRAS-CoV-2 chez les enfants et les adolescents provoquent une maladie moins grave et moins de décès que chez les adultes. Bien qu'une évolution moins grave de l'infection soit un résultat positif, on s'inquiète du fait que des symptômes légers aient pu conduire à moins de t...ests, ce qui a entraîné un nombre moins important de cas identifiés de COVID-19 chez les enfants. Si les enfants présentant des symptômes légers ou inexistants transmettent la maladie, ils peuvent agir comme des vecteurs de transmission au sein de leur communauté. Il est essentiel de comprendre les symptômes, l'infectivité et les modes de transmission du SRAS-CoV-2 chez les enfants et les adolescents pour développer, adapter et améliorer les mesures de contrôle du COVID-19 à tous les âges. Ce document est un résumé des connaissances actuelles concernant l'acquisition et la transmission de l'infection par le SRAS-CoV-2 et les symptômes de la maladie COVID-19 chez les enfants et les adolescents. Il vise à éclairer les décisions, en fonction des contextes locaux, sur la meilleure façon de maintenir ouvertes les écoles, les jardins d'enfants et les crèches et sur les conseils à appliquer en matière de mixité intergénérationnelle.
more
This bi-weekly brief details the latest developments in scientific knowledge and public health policy from around the world as well as updates to the COVID-19-related guidance from Africa CDC, WHO and other public health agencies.
Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi.
AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines making infections ha...rder to treat and increasing the risk of disease spread, severe illness and death. As a result, the medicines become ineffective and infections persist in the body, increasing the risk of spread to others.
Antimicrobials - including antibiotics, antivirals, antifungals and antiparasitics - are medicines used to prevent and treat infections in humans, animals and plants. Microorganisms that develop antimicrobial resistance are sometimes referred to as “superbugs”.
more
Antimicrobial resistance (AMR) – the ability of microorganisms to resist antimicrobial treatments, especially antibiotics – has a direct impact on human and animal health and carries a heavy economic burden due to higher costs of treatments and reduced productivity caused by sickness. AMR is res...ponsible for an estimated 33,000 deaths per year in the EU. It is also estimated that AMR costs the EU €1.5 billion per year in healthcare costs and productivity losses.
more
MEDBOX Issue Brief no. 19: World TB Day: Invest to end TB. Save Lives
Informationen rund um Einreise, Aufenthalt, medizinische Versorgung, aktuelle Updates für Geflüchtete aus der Ukraine und Behörden, Kommunen, Gemeinschaftsunterkünfte
the Lancet Infectious Diseases Published online March 22, 2022 https://daoi.org/10.1016/S1473-3099(22)00214-6
Lancet Infect Dis 2022 Published Online April 8, 2022 https://doi.org/10.1016/S1473-3099(22)00225-
This document aims to provide interim guidance for microbiology and virology experts, other laboratory professionals, laboratory managers, infectious disease programme managers, public health professionals and other stakeholders that provide primary, confirmatory or advanced testing for SARS-CoV-2, ...including genomic sequencing, or are involved in making decisions on establishing or scaling up capability and capacity to detect and characterize circulating SARS-CoV-2 variants.
more
The WHO Global Tuberculosis Report 2022 provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets.
...
The 2022 edition of the report is as usual, based primarily on data gathered by WHO from national ministries of health in annual rounds of data collection. In 2022, 202 countries and territories with more than 99% of the world’s population and TB cases reported data
more
Building on the 2021 Interim guidance, this second version and update, incorporates the lessons and feedback from the hepatitis pilots that successfully demonstrated the feasibility of measuring hepatitis B and C impact targets to demonstrate elimination, whilst highlighting challenges caused by hig...h disease burden in some countries, as well as delays in reaching mortality targets due to the long natural history of disease progression to liver cirrhosis and hepatocellular carcinoma.
The path to elimination provides a framework with 3 levels of achievements for which WHO certification is available. Each stepwise progression from bronze to silver to gold tiers will promote an iterative expansion of prevention, diagnosis and treatment services for viral hepatitis services and strengthen measurement systems to support attainment of the 2030 elimination goals.
This updated version also includes changes, clarifications and new guidance on alternative measurement approaches for country validation of elimination. Through the validation process, WHO and partners continue to provide country support for strengthening health system capacity and patient-centred services that respect and protect the human rights of people living with viral hepatitis and ensures meaningful engagement of communities in the national, regional and global viral hepatitis response.
more